In his weekly clinical update, Dr. Griffin discusses the public health significance of finding autochthonous melioidosis cases in the continental United States, human neural larva migrans caused by Ophidascaris robertsi ascarid, Project nextgen awards over $1.4 billion to develop the future of COVID-19 vaccines and therapeutics, excess all-cause mortality in China after ending the zero COVID policy, international pediatric COVID-19 severity over the course of the pandemic, differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination, Pfizer and BioNTech receive positive CHMP opinion for Omicron XBB.1.5-adapted COVID-19 vaccine in the European Union, clinical antiviral efficacy of Remdesivir in COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, clinical outcomes associated with overestimation of oxygen saturation by pulse oximetry in patients hospitalized with COVID-19, risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination.
TWiV reviews approvals of the first gene therapy for severe hemophilia A in adults and a monoclonal antibody to prevent RSV respiratory disease in babies and toddlers, and a common allele of HLA that mediates asymptomatic SARS-CoV-2 infection through pre-existing T cell immunity due to previous exposure to common cold coronaviruses.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Rich Condit, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.